Published in Eur J Haematol on November 28, 2009
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
Crosstalk between Bcl-2 family and Ras family small GTPases: potential cell fate regulation? Front Oncol (2013) 0.86
Ras and rheb signaling in survival and cell death. Cancers (Basel) (2013) 0.78
Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways. J Cancer Res Clin Oncol (2014) 0.77
Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors. PLoS One (2014) 0.76
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins. Int J Med Sci (2016) 0.75
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol (2017) 0.75
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull (2006) 4.42
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol (2008) 3.12
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol (2010) 2.64
Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci (2007) 2.61
Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol (2009) 2.52
MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep (2006) 2.29
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res (2007) 2.25
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol (2005) 2.24
MicroRNA-143 and -145 in colon cancer. DNA Cell Biol (2007) 2.24
Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology (2009) 2.21
EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood (2011) 2.18
Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med (2012) 2.06
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol (2012) 1.97
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood (2003) 1.87
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol (2008) 1.81
Integrin activation and matrix binding mediate cellular responses to mechanical stretch. J Biol Chem (2005) 1.80
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood (2011) 1.79
Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol (2013) 1.70
A randomized control trial of bi-monthly versus bi-weekly endoscopic variceal ligation of esophageal varices. Am J Gastroenterol (2005) 1.68
Self-assembling peptide nanofiber scaffolds, platelet-rich plasma, and mesenchymal stem cells for injectable bone regeneration with tissue engineering. J Craniofac Surg (2009) 1.67
BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood (2010) 1.67
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood (2005) 1.66
Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension (2005) 1.62
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res (2010) 1.59
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene (2002) 1.56
Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood (2008) 1.53
Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leuk Lymphoma (2014) 1.50
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. Cancer Sci (2012) 1.48
Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci (2010) 1.46
Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther (2010) 1.43
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer (2005) 1.42
MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett (2011) 1.42
Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett (2010) 1.42
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res (2012) 1.42
Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J (2007) 1.41
Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med (2003) 1.40
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol (2014) 1.39
Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci (2008) 1.36
BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A (2008) 1.34
Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. Bioorg Med Chem (2007) 1.33
A novel optical assay system for the quantitative measurement of chemotaxis. J Immunol Methods (2003) 1.30
Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med (2006) 1.29
Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice. Biochem Biophys Res Commun (2004) 1.27
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood (2009) 1.21
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol (2007) 1.20
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol (2013) 1.14
BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol (2005) 1.13
Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity. Pathol Int (2009) 1.13
Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol (2008) 1.13
Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation. Arterioscler Thromb Vasc Biol (2004) 1.12
Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun (2009) 1.12
Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene (2003) 1.12
Rho-kinase and myosin II activities are required for cell type and environment specific migration. Genes Cells (2005) 1.11
Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Int J Hematol (2008) 1.11
The CML stem cell: evolution of the progenitor. Cell Cycle (2009) 1.10
Nucleophosmin: a versatile molecule associated with hematological malignancies. Cancer Sci (2006) 1.09
Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. Eur J Haematol (2009) 1.08
CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases. Int J Hematol (2005) 1.08
Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. Leuk Res (2009) 1.08
Transforming mutations of RAC guanosine triphosphatases in human cancers. Proc Natl Acad Sci U S A (2013) 1.07
Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. Am J Pathol (2010) 1.06
Tumor-suppressive microRNA-145 targets catenin δ-1 to regulate Wnt/β-catenin signaling in human colon cancer cells. Cancer Lett (2013) 1.05